Randomised, double-blind, placebo-controlled three-month trial of Biobran MGN-3 in patients with persistent symptoms attributed to Lyme borreliosis

Trial Profile

Randomised, double-blind, placebo-controlled three-month trial of Biobran MGN-3 in patients with persistent symptoms attributed to Lyme borreliosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs MGN 3 (Primary)
  • Indications Lyme disease
  • Focus Pharmacodynamics
  • Sponsors Daiwa Pharmaceutical
  • Most Recent Events

    • 03 Jul 2017 New trial record
    • 27 Jun 2017 Status has been changed from Not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top